Pharmaceutical comprising sustained-release microspheres including GLP-1 analogue or pharmaceutically acceptable salt thereof

A pharmaceutical composition for treatment of diabetes, type 2 diabetes, beta-cell function preservation, obesity, non-alcoholic steatohepatitis or neurodegenerative diseases, comprising a sustained-release microsphere containing semaglutide freebase and a biodegradable polymer,

• wherein the biodegradable polymer comprises two different types of polylactide-co-glycolide (PLGA) with different lactide:
• glycolide molar ratios and/or different intrinsic viscosities,
• wherein the lactide:
• glycolide molar ratios are from 75:25 to 50:50,
• wherein each of the two types of PLGA has an intrinsic viscosity of 0.16-0.44 dL/g, the intrinsic viscosity being measured at a concentration of 0.1% (w/v) in chloroform at 25° C. using an Ubbelohde viscometer,
• wherein the content ratio of said two different types of PLGA is from 1:2 to 2:1,
• wherein said two different types of PLGA are acid terminated,
• wherein the semaglutide freebase is comprised in 3-12% by weight as semaglutide, based on the total weight of the microsphere,
• wherein the semaglutide freebase is released from the sustained-release microsphere by less than 10% within 24 hours after administration, and
• wherein the sustained-release microsphere releases the semaglutide freebase for one month or more.